Abstract
Broussonetia kazinoki (BK) has been used as a traditional medicine to improve vision, as well as for inflammatory and infectious diseases. In the present study, we investigated the effects and molecular mechanism of the ethanolic extract of BK on cell proliferation, migration and tubular formation in vascular endothelial growth factor-A (VEGF-A)-treated human umbilical vein endothelial cells. BK treatment inhibited VEGF-A-stimulated endothelial cell proliferation through the downregulation of cell cycle-related proteins including cyclin-dependent kinases and cyclins. Moreover, BK treatment suppressed cell migration and tubular formation in response to VEGF-A. These anti-angiogenic activities of BK were associated with the inactivation of mitogenic signaling pathways including extracellular signal-regulated kinase, Akt and p70S6K, and the subsequent downregulation of VEGFR-2 and matrix metalloproteinase-2. Taken together, these findings suggest further evaluation and development of BK as a potential therapeutic agent for the treatment and prevention of angiogenesis-related diseases including cancer.
Introduction
Angiogenesis, the formation of new blood vessels from pre-existing ones, is a critical process in both physiological development and pathological conditions. While essential for wound healing, it is a hallmark of cancer progression, enabling tumors to acquire the nutrients and oxygen necessary for sustained growth and metastasis. Current anti-angiogenic therapies, such as bevacizumab, primarily target the Vascular Endothelial Growth Factor (VEGF) pathway. However, the development of drug resistance and cancer recurrence remains a significant challenge in clinical oncology.
Researchers are increasingly looking toward natural sources for more robust, multi-targeted anti-angiogenic agents. Broussonetia kazinoki (BK), commonly known as the Paper Mulberry, is a plant used in traditional Asian medicine for treating inflammatory and infectious diseases. This study investigates whether an ethanolic extract of BK can disrupt the molecular machinery that endothelial cells use to build new vessels.
Methods
The study utilized Human Umbilical Vein Endothelial Cells (HUVECs) (passages 4–6) as a primary model system. Cells were treated with an ethanolic extract of BK twigs and stimulated with VEGF-A to simulate a pro-angiogenic environment.
Key experimental techniques included:
- Proliferation and Viability Assays: Measuring cell growth and ensuring the extract was not cytotoxic.
- Wound-Healing Assay: Quantifying the speed at which cells migrate to fill a "scratch" in a culture dish.
- Tube Formation Assay: Observing the organization of endothelial cells into capillary-like structures on Matrigel.
- Western Blotting: Analyzing the expression and phosphorylation of signaling proteins (ERK, Akt, p70S6K) and cell cycle regulators (Cdk2, Cdk4, cyclins).
- Gelatin Zymography: Measuring the enzymatic activity of Matrix Metalloproteinase-2 (MMP-2).
Key Results
Inhibition of Proliferation and Cell Cycle Arrest
BK treatment (0.1–10 µg/ml) significantly inhibited VEGF-A-stimulated HUVEC proliferation in a dose-dependent manner. Importantly, this effect was not due to cytotoxicity, as cell viability remained near 100% across all tested concentrations. The growth inhibition was linked to cell cycle arrest, characterized by the downregulation of cyclin-dependent kinases (Cdk2, Cdk4) and cyclins (D and E), as well as reduced phosphorylation of the retinoblastoma protein (pRb).
Suppression of Cell Migration and Structure
A critical step in angiogenesis is the migration of endothelial cells toward a growth signal. BK treatment significantly suppressed VEGF-A-induced cell migration. At a concentration of 10 µg/ml, the migratory capacity of HUVECs was returned to near-baseline levels, as demonstrated by both quantitative relative units and visual wound-healing assays. Additionally, BK treatment nearly halved the number of branching points in the tube formation assay, effectively preventing the cells from organizing into vessel-like structures.
Molecular Signaling and Enzymatic Activity
The anti-angiogenic effects of BK were mediated by the inactivation of major mitogenic signaling hubs. BK markedly suppressed the phosphorylation of ERK, Akt, and p70S6K within 15 minutes of VEGF-A stimulation. Furthermore, BK treatment led to a decrease in the expression of VEGFR-2, the primary receptor for VEGF-A, and MMP-2, an enzyme essential for degrading the extracellular matrix during cell invasion. Gelatin zymography confirmed that BK treatment significantly reduced the activation of MMP-2 in the cell culture medium.
Discussion and Key Insights
The study highlights several key mechanisms by which BK exerts its anti-angiogenic effects:
- Non-Cytotoxic Growth Control: Unlike many chemotherapeutics, BK inhibits growth by "pausing" the cell cycle rather than inducing cell death, which may offer a better safety profile.
- Multi-Targeted Approach: By simultaneously inhibiting ERK, Akt, and p70S6K pathways, BK disrupts multiple survival and growth signals, potentially making it harder for cells to develop resistance.
- Disrupting Tissue Remodeling: By suppressing MMP-2, the "drill" cells use to move through tissue, BK effectively locks endothelial cells in place, preventing them from forming new vessels.
Limitations and Future Work
While these in vitro results are promising, the study was conducted entirely in a laboratory setting. The complex environment of a living organism—including blood flow, immune interactions, and metabolic clearance—could influence the extract's efficacy. Additionally, as a whole ethanolic extract was used, the specific bioactive compounds responsible for these effects remain unidentified.
Future research should focus on bioassay-guided fractionation to isolate the specific active ingredients, followed by in vivo studies using animal models to confirm the anti-tumor potential in a complex biological system.
Summary updated